ClinicalTrials.gg
Active, not recruitingNCT03777384Updated Nov 5, 2026

EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers

An observational study in Oropharyngeal Cancer, sponsored by Sanford Health. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Sanford Health · Observational

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.

Enrollment
25th of 36
75 · median 205
Started
2018
with 20 others
Observational
36 of 235
9 open now
Primary completion
2027-07
later than 39 of 97 live
Registered
124th of 235
by date

Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 25th largest by enrollment of the 36 observational ones that give a count, is one of 21 that started in 2018, is one of 36 observational ones, reaches primary completion later than 39 of the 97 other live ones, and was the 124th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Oropharyngeal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A prospective, observational study evaluating the durability of local/regional control of previously published de-escalated radiotherapy protocols for patients with P16 positive oropharynx cancers who have minimal nicotine exposure who are not current uses (\< 10 pack year smoking history; \< 10 year history of any nicotine product [electronic cigarette, chewing tobacco]). Quality of Life measures will also be collected.

Read the detailed description

This is a prospective, single-site, observational study in head and neck cancer participants. The purpose of this study is to provide a systematic platform to analyze, interpret, and track radiation dose de-escalation therapy and associated participant outcomes from treatments identified by these results.

Participants will be asked to complete quality of life questionnaires at regular time points before, during, and after treatment.

03

Conditions studied

  • Oropharyngeal Cancer

Keywords

  • oropharynx
  • head and neck cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with HPV positive oropharynx cancers who have minimal nicotine exposure who are not current uses (\< 10 pack year smoking history; \< 10 year history of any nicotine product [electronic cigarette, chewing tobacco]).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Histologic confirmation of tumor of the oropharynx
  • Radiation therapy (de-escalated head and neck irradiation) decision has been made
  • Human Papilloma Virus (HPV) associated cancer as determined by positive p16 immunohistochemistry

    • HPV positivity is defined by p16 IHC staining of > 70% of tumor cells (strong and diffuse nuclear and cytoplasmic staining)
    • For cases that are indeterminate or if p16 testing cannot be accurately performed, HPV positivity can be confirmed by high-risk HPV DNA Testing which covers the following HPV subtypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
  • \< 10 pack year smoking history OR \< 10 year nicotine use history
  • No current tobacco/nicotine use (including electronic cigarettes and chewing tobacco)
  • T1-T3, N0-N2 (AJCC8) requiring definitive therapy greater than surgery alone
  • Ability to provide informed written consent
  • Willingness to return to Sanford Cancer Center for follow-up
  • > 12 weeks
  • performance status \< 3 (Appendix B)
  • Adequate organ function for chemotherapy and radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Any of the following because the inclusion criteria require delivery of radiotherapy and chemotherapy which is known to be genotoxic, and is associated with mutagenic and teratogenic effects: pregnant women, nursing women, men or women of who are unwilling to employ adequate .
  • Prior head and neck radiotherapy
  • Any factor precluding safe delivery of chemotherapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
75 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The durability of local disease control of de-escalated radiotherapy protocols in the community cancer center setting.

    Number of participants who remain disease free from the end of treatment to 5 years after treatment.

    Time frame: End of treatment to 5 years after end of treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2018 (actual). Primary completion is estimated for Jul 2027, 105 months after the start.

Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 105 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jul 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2018
First posted
Dec 17, 2018
StartActual
Oct 12, 2018
Primary completionEst.
Jul 2027was Jul 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jul 2027
Nov 5, 2026
Study completion
Dec 2026→Dec 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jul 2026→Jul 2027
    Study completion Dec 2026→Dec 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03777384
Lead sponsor
Sanford Health
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Oct 12, 2018
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Miran Blanchard, MD
study chair · Sanford Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion